Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

26.3%

5 terminated/withdrawn out of 19 trials

Success Rate

72.2%

-14.3% vs industry average

Late-Stage Pipeline

32%

6 trials in Phase 3/4

Results Transparency

23%

3 of 13 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1

7(36.8%)

Phase 2

6(31.6%)

Phase 3

6(31.6%)

19Total

Phase 1(7)

Phase 2(6)

Phase 3(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials

NCT01480232Phase 2Terminated

A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence

Role: collaborator

NCT01716975Phase 3Completed

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Role: lead

NCT01969136Phase 3Terminated

Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

Role: lead

NCT02004392Phase 3Terminated

Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025

Role: lead

NCT01714713Phase 3Completed

A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Role: lead

NCT01969123Phase 3Terminated

Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

Role: lead

NCT01714661Phase 3Completed

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Role: lead

NCT02149160Phase 2Unknown

Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation

Role: lead

NCT02246075Phase 2Withdrawn

Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine

Role: lead

NCT01984723Phase 1Completed

EVP-6124 Renal Impairment Study

Role: lead

NCT01984736Phase 1Completed

EVP-6124 Hepatic Impairment Study

Role: lead

NCT02037074Phase 1Completed

Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics

Role: lead

NCT02001389Phase 1Completed

Study of EVP-6308 to Assess the Dose- and Concentration-dependent Displacement of [18F]MNI-659 by EVP-6308

Role: lead

NCT01487135Phase 1Completed

Phase 1 Study to Assess the Effects of EVP-6124 on the QT/QTc Interval in Healthy Subjects

Role: lead

NCT00968851Phase 2Completed

Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia

Role: lead

NCT01073228Phase 2Completed

Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease

Role: lead

NCT01661673Phase 2Completed

Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease

Role: lead

NCT01556763Phase 1Completed

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia

Role: lead

NCT00766363Phase 1Completed

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease

Role: lead

All 19 trials loaded